Human Leukocyte Antigen (HLA) Testing in Pharmacogenomics

Area of Science:

• Immunogenetics
• Pharmacogenomics

Background:

• The human leukocyte antigen (HLA) system, located on chromosome 6, is highly polymorphic and critical for immune responses.
• Traditional histocompatibility testing focuses on allele identification for transplantation.
• Emerging applications link specific HLA alleles to disease susceptibility and adverse drug reactions (ADRs).

Purpose of the Study:

• To introduce the HLA system and its genetic basis.
• To provide an overview of HLA testing technologies, particularly in pharmacogenomics.
• To detail HLA alleles associated with ADRs.

Main Methods:

• Overview of molecular methods for HLA typing, including commercially available kits.
• Discussion of pharmacogenomic laboratory approaches, including single nucleotide variant querying.
• Exploration of technologies for determining the presence or absence of specific HLA alleles.

Main Results:

• HLA alleles are associated with varying risks of diseases and adverse drug reactions.
• Testing methodologies are evolving to meet the demands of pharmacogenomic applications.
• Direct allele testing and indirect variant querying are employed.

Conclusions:

• HLA typing plays a vital role beyond transplantation, impacting personalized medicine and drug safety.
• Understanding HLA allele associations is essential for predicting and mitigating ADRs.
• Advancements in molecular diagnostics facilitate targeted HLA testing for clinical applications.